Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of PHP1003 in Chinese patients with moderate-to-severe thyroid eye disease
CTR20244055Phase 2Active
- Sponsor
- Pulekang Pharmaceutical
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of KHN939 in Graves Orbitopathy (GO), sponsored by Pulekang Pharmaceutical. Started Nov 2024; status: active.
02
Drugs
KHN939
03
Conditions
Graves Orbitopathy (GO)
Beyond the preview
Go deeper on CTR20244055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20244055.